{"id":"clobenoside","rwe":[{"pmid":"3358049","year":"1988","title":"[Activity testing of clobenoside gel in the treatment of chronic venous insufficiency].","finding":"","journal":"Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis","studyType":"Clinical Study"},{"pmid":"4062437","year":"1985","title":"Effects of two venotropic drugs on inactivation and O-methylation of catecholamines in an isolated canine vein.","finding":"","journal":"Archives internationales de pharmacodynamie et de therapie","studyType":"Clinical Study"},{"pmid":"4039572","year":"1985","title":"[Edema-protective effect of clobenoside].","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"3835823","year":"1985","title":"Inhibitors of glycoprotein biosynthesis.","finding":"","journal":"Advances in enzyme regulation","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"arvigol","offLabel":[],"synonyms":["clobenosid","clobenoside","arvigol","floganol"],"timeline":[],"approvals":[],"brandName":"Arvigol","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have a special messenger system that helps them communicate with each other. Arvigol may block or slow down this messenger system, which can affect how cells behave and respond to signals. This can potentially lead to changes in various bodily functions, but more research is needed to understand how it works and what effects it may have on the body.","oneSentence":"Arvigol is thought to work by inhibiting the activity of certain enzymes or proteins, although the exact mechanism is not well understood.","technicalDetail":"CLOBENOSIDE is believed to exert its effects through the inhibition of certain enzymes or proteins, although the specific molecular targets and pathways involved are not yet fully elucidated."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/683","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOBENOSIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:08:41.652678","biosimilars":[],"competitors":[],"genericName":"clobenoside","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"8427MP5VHD","CHEBI":"CHEBI:135801","INN_ID":"2947","UMLSCUI":"C0055893","ChEMBL_ID":"CHEMBL3989839","PUBCHEM_CID":"65769","MESH_SUPPLEMENTAL_RECORD_UI":"C044699"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1988 Feb 23","pmid":"3358049","title":"[Activity testing of clobenoside gel in the treatment of chronic venous insufficiency].","journal":"Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis"},{"date":"1985 Oct","pmid":"4062437","title":"Effects of two venotropic drugs on inactivation and O-methylation of catecholamines in an isolated canine vein.","journal":"Archives internationales de pharmacodynamie et de therapie"},{"date":"1985","pmid":"4039572","title":"[Edema-protective effect of clobenoside].","journal":"Arzneimittel-Forschung"},{"date":"1985","pmid":"3835823","title":"Inhibitors of glycoprotein biosynthesis.","journal":"Advances in enzyme regulation"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arvigol, also known as CLOBENOSIDE, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Arvigol's safety profile and potential side effects are not well-documented. Further research is needed to understand its mechanism of action and potential therapeutic applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}